Abstract
Recent work at AstraZeneca resulted in the discovery of novel pain-killing peptides from the venom of the Chilean pink tarantula [1–3]. These peptides, designated Grammostola spatulata analgesic factors (GsAF), were found effective in a variety of animal models of moderate-to-severe pain. They were also found to exhibit activity in models of neuropathic pain, and as such represent a potentially interesting approach to the amelioration of pain associated with cancer and the post-operative surgical period.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Lampe, R.A., Sachs, F., US Patent 5,756,663, May 26, 1998.
Lampe, R.A. US Patent 5,776,896, July 7, 1998.
Lampe, R.A. US Patent 5,807,821, Sept. 15, 1998.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Liu, Rq., Jacobs, R.T., Spreen, R.C., Barany, G. (2001). Synthesis and Characterization of the Pain-Killing Peptide Grammostola spatulata Analgesic Factor (GsAF-1) Containing Three Disulfide Bonds. In: Lebl, M., Houghten, R.A. (eds) Peptides: The Wave of the Future. American Peptide Symposia, vol 7. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-0464-0_191
Download citation
DOI: https://doi.org/10.1007/978-94-010-0464-0_191
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-3905-5
Online ISBN: 978-94-010-0464-0
eBook Packages: Springer Book Archive